
CAC builds biofuel plant for OMV
CAC has been assigned by OMV with overall responsibility for the construction of a biofuel plant in which biogenic input materials are processed...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...

Targeting SARS-CoV-2 differently
Using X-ray crystallography, Sebastian Günther and colleagues screened more than 5,000 drug compounds, identified seven compounds that bind to Mpro,...

EU orders 100 million additional doses from Biontech
To avoid supply shortages that could occur as a result of restricted use of adenoviral COVID-19 vaccines, the European Commission has acquired...

B.1.1.7 variant associated with higher mortality
Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

MaxiVAX and Minaris Regenerative Medicine ink contract
Under the contract, Minaris will be responsible for the GMP manufacturing, freezing and shipping of MVX-ONCO-2, a cell-based immunotherapy for the...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...